UK and US VC performance have been converging - but it's not all plain sailing
Medtech investing is tough - it's tough technically, regulatorily and commercially.
This guest blog is written by Paul Vickery, venture partner for NESTA's Venture Capital Fund.
The new line-up of top 100 UK tech companies shows just how disruptive and exciting this market can be.
Two events that remind me that although we are a UK based fund, investing in UK technology, the markets that our businesses can address are global.
Last week I went to a couple of interesting events which highlighted some of the key questions facing the Venture industry and the broader issue of access to capital for high growth innovative businesses.
Find out why we have invested in a semiconductor company, and the criteria we use when assessing the market
NESTA's research team have just completed a review of the UK early stage Venture Industry
Welcome to my new Investments blog. I'll be sharing insights with you about growth companies, early stage investments and the wider entrepreneurial and venture industry
![Twitter icon [original]](http://admin.nesta.org.uk/library/images/Twitter-button_34x35.jpg "Twitter icon [original]"){kind=small}
Follow our daily updates on Twitter @nesta_uk
![Linked in icon [original]](http://admin.nesta.org.uk/library/images/LinkedIn_button_34x35.jpg "Linked in icon [original]"){kind=small}
Take part in the discussion on our LinkedIn group
![Facebook icon [original]](http://admin.nesta.org.uk/library/images/facebook.jpg "Facebook icon [original]"){kind=small}
Share your views on our Facebook page
Sign up for our regular updates for the latest news and opportunities.
T +44 (0)20 7438 2500
F +44 (0)20 7438 2501
Nesta Operating Company, a company limited by guarantee registered in England and Wales with company number 7706036 and charity number 1144091. Registered as a charity in Scotland number SC042833.
